Objective: Insulin resistance in visceral obesity is substantially driven by adipose tissue inflammation, particularly by macrophages accumulating in obese adipose tissue. In contrast, adipose tissue macrophages express the hemoglobin scavenger receptor (CD163) and heme oxygenase-1 (gene: HMOX1) that together protect from oxidative stress. Our aim was to evaluate the expression of CD163 and HMOX1 in intra-abdominal visceral (omental) and subcutaneous adipose tissue as well as circulating soluble CD163 concentrations in human obesity and its association with adipose tissue inflammation, body fat distribution and insulin resistance. Methods: CD163, HMOX1 and CD68 mRNA expression in visceral and subcutaneous adipose tissue, serum concentration of soluble CD163 in morbidly obese patients (body mass index (BMI) 440 kg m À2 ), who underwent laparoscopic surgery for gastric banding (n ¼ 20), matched for age and sex to controls (BMIo30 kg m À2 ; n ¼ 20) was analyzed. Results: CD163 expression was highly upregulated in human adipose tissue and soluble CD163 serum concentration was elevated in obese vs lean subjects. HMOX1 was upregulated in adipose tissue by obesity as well and expressed predominantly in macrophages. Although CD163 expression strictly correlated with macrophage abundance, HMOX1 was additionally upregulated within macrophages. This upregulation was significantly lower in visceral compared with subcutaneous adipose tissue. Strikingly, relative visceral adipose tissue expression of HMOX1 negatively correlated with waist-to-hip ratio and the homeostasis model assessment of insulin resistance (both P ¼ 0.024). Conclusions: Visceral obesity is associated with defective upregulation of heme oxygenase-1 in visceral adipose tissue. A lack of this antioxidative and anti-inflammatory enzyme in visceral adipose tissue could contribute to the development of insulin resistance.
Introduction
Obesity, particularly visceral obesity, which is reflected by an elevated waist-to-hip ratio (WHR), is one of the major risk factors for the development of insulin resistance, which is a fundamental step towards type 2 diabetes mellitus. 1 Obesity and insulin resistance are associated with a chronic lowgrade inflammation that is determined by increased plasma levels of inflammatory parameters in patients and different animal models of obesity. 2, 3 The main origin of this systemic inflammatory response is located in adipose tissue. 4 Within adipose tissue, inflammatory mediators are predominantly produced by non-adipocytes such as macrophages. 5, 6 Obesity-associated adipose tissue inflammation is characterized by an increased abundance of adipose tissue macrophages in mice; 6, 7 several studies have confirmed a correlation between body mass index (BMI) and adipose tissue macrophage numbers in humans particularly in the metabolically relevant visceral adipose tissue. [8] [9] [10] [11] Therefore, adipose tissue macrophages are assumed to critically contribute to the pathogenesis of type 2 diabetes mellitus and the metabolic syndrome by driving obesity-associated chronic inflammation. In contrast, adipose tissue macrophages may also have cytoprotective anti-inflammatory properties, as identified by the expression of several markers that determine an alternatively activated, anti-inflammatory macrophage type, 12, 13 for instance, the hemoglobin scavenger receptor CD163. 10, 14 CD163 is exclusively expressed on monocytes and macrophages and mediates endocytosis of haptoglobinhemoglobin complexes, 15 thereby preventing oxidative and nitrosative toxicity emerging upon red blood cell hemolysis. 16 Moreover, CD163-mediated uptake of hemoglobin into the macrophage fuels an anti-inflammatory response driven by heme oxygenase-1 activity, leading to potent anti-inflammatory heme metabolites. 17, 18 A soluble form of CD163 (sCD163) of unknown function is found in serum and its concentration is elevated in sepsis, myeloid leukemia, Gaucher disease 19 and atherosclerosis. 20 Moreover, sCD163 serum concentration has been shown to increase with obesity in patients with chronic kidney disease. 21 As CD163 is known to be highly expressed on adipose tissue macrophages, it may be speculated that the CD163/ heme oxygenase-1 system is involved in obesity-driven adipose tissue inflammation with potential consequences on insulin sensitivity. Indeed, recent animal studies showed that the administration of heme oxygenase-inducers improve insulin sensitivity. 22, 23 In our study, we aimed at investigating whether the expression of CD163 and heme oxygenase-1 (gene: HMOX1) is regulated by obesity in subcutaneous and the metabolically more relevant visceral adipose tissue and whether the expression of these molecules is related to adipose tissue inflammation, body fat distribution and insulin resistance. We found that CD163 gene expression is elevated in obese adipose tissue and strictly correlates with macrophage abundance in adipose tissue. Adipose tissue HMOX1 expression was upregulated by obesity and exceeded macrophage abundance indicating additional upregulation within macrophages. Macrophage HMOX1 upregulation by obesity was significantly lower in visceral compared with subcutaneous adipose tissue. Relative visceral adipose expression of HMOX1 negatively correlated with WHR, indicating alterations in heme oxygenase-1 regulation by the expansion of visceral adipose tissue that could abolish protection from oxidative stress. Moreover, visceral HMOX1 expression negatively correlated with insulin resistance as assessed by the homeostasis model assessment of insulin resistance (HOMA-IR). These data indicate that visceral heme oxygenase-1 expression is determined by body fat distribution and could be a factor preventing or attenuating obesity-induced insulin resistance.
Methods

Patients
Paired samples of visceral (omental) and subcutaneous adipose tissue were obtained from 40 Caucasian men (n ¼ 12) and women (n ¼ 28). Morbidly obese patients (BMI 440 kg m
À2
) who underwent laparoscopic bariatric surgery (n ¼ 20) were matched for age and sex with control subjects (BMIo30 kg m
) undergoing laparoscopic cholecystectomy (n ¼ 15), fundoplicatio (n ¼ 3), resection of liver cysts (n ¼ 1) or partial colon resection (n ¼ 1). Adipose tissue samples were taken from similar locations in all patients. Criteria for exclusion were the presence of any infectious, inflammatory, neoplastic or systemic disease, diabetes (excluded by fasting plasma glucose or the use of anti-diabetic drugs) or other uncontrolled endocrine disease and the current use of antibiotics, anti-inflammatory or anti-obesity drugs. The study was approved by the ethics committee of the Medical University of Vienna. All subjects gave written informed consent before taking part in the study.
Metabolic parameter
The HOMA-IR was calculated using fasting insulin and glucose as described earlier. 24 Characteristics of the study population including serum C-reactive protein have been published elsewhere. Immunoblotting Adipose tissue (300 mg) was homogenized and lysed on ice for 30 min in 0.5 ml tris-buffered saline, pH 7.4, containing 1% Triton X-100 and protease inhibitors. The tissue extract was cleared from fat, nuclei and debris by centrifugation, and identical amounts of protein, as detected by BCA assay (Pierce, Rockford, IL, USA), were separated by SDS-PAGE and blotted onto polyvinylidene fluoride membranes (Amersham, Little Chalfont, UK). Heme oxygenase was determined using respective rabbit polyclonal antibody from BioVision (Mountain View, CA, USA) and b-acting using mouse monoclonal antibody from Santa Cruz Biotech (Santa Cruz, CA, USA) followed by respective horseradish peroxidaselabelled secondary antibodies (Accurate, Westbury, NY, USA).
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Chemiluminescence was generated by BM chemiluminescence substrate (Roche, Mannheim, Germany)
Adipose tissue cell fractionation Subcutaneous adipose tissue (n ¼ 5) was fractionated into cell populations as described previously. 26 Briefly, visible vessels and connective tissue were carefully removed and tissue cut into pieces, washed in phosphate-buffered saline and digested for 1 h with 35 mg ml À1 liberase 3 (Roche) and 50 U ml
À1
DNAse I (Sigma, St Louis, MI, USA). The digested tissue was passed through a 250 mM nylon mesh and centrifuged to obtain adipocytes (floating) and the stromal vascular cell fraction (pellet), and 'matrix'. 27 Following hemolysis, stromal vascular cells were subjected to magnetic-activated cell sorting of CD14 þ cells (Miltenyi Biotec, Bergisch Gladbach, Germany)
to isolate adipose tissue macrophages.
sCD163
A commercial ELISA kit (IQ Products BV, Groningen, The Netherlands) was used to quantitate sCD163 in serum samples according to the manufacturer's instructions. 
Statistical analysis
Results
Adipose tissue CD163 expression and serum sCD163 concentration are elevated in obesity The expression of the hemoglobin scavenger receptor gene CD163 was highly upregulated in human adipose tissue in obese compared with control subjects (Figure 1a ). Upregulation by obesity was similar in intra-abdominal visceral and subcutaneous adipose tissue. Similarly, expression of the macrophage marker CD68 (Figure 1b ) and macrophage count 25 was upregulated by obesity in both visceral and subcutaneous adipose tissue to a comparable extent. CD163 expression strictly correlated with CD68 (r ¼ 0.952 and 0.920 for obese visceral and subcutaneous adipose tissue, respectively; Po0.001 for both). Accordingly, the ratio of CD163 and CD68 expression in all groups was close to 1 (Figure 1c ), indicating that CD163 expression in the adipose tissue is directly linked to macrophage abundance without further regulation within macrophages. Also sCD163 serum concentration was significantly elevated in the obese (Figure 1d ). However, sCD163 concentrations neither correlated with adipose tissue CD163 expression nor serum C-reactive protein within obese or control subjects (data not shown).
Regulation of heme oxygenase-1 expression in obesity
In human adipose tissue, the gene for hemoglobin-metabolizing enzyme heme oxygenase-1 (HMOX1) was markedly upregulated by obesity (Figure 2a ). HMOX1 gene expression data were confirmed on the protein level by immunoblot analyses (Figure 2b ). Adipose tissue HMOX1 expression was essentially confined to CD14 þ cells consisting for the most part of macrophages (Figure 2d ). The mean expression of HMOX1 in obese was about twice as high in subcutaneous compared with visceral adipose tissue, but this differences was not statistically significant because of large interindividual variation (P ¼ 0.11; Figure 2a ). The trend towards lower visceral adipose expression of heme oxygenase-1 in obesity was also apparent on the protein level ( Figure 2b ). As the expression of both HMOX1 (Figure 2d ) and CD68 26 is confined to macrophages in adipose tissue and CD68 accurately reflected the number of macrophages in adipose tissue sections of the study population (Huber et al. 25 and Adipose heme oxygenase-1 and insulin sensitivity S Shakeri-Manesch et al data not shown), the ratio of HMOX1 and CD68 was calculated as a measure of HMOX1 expression in adipose tissue macrophages. HMOX1/CD68 was significantly elevated by obesity in subcutaneous and visceral adipose tissue (Figure 2d ). Of note, the increase in macrophage HMOX1 expression was significantly less pronounced in visceral compared with subcutaneous adipose tissue (P ¼ 0.020; Figure 2d ).
High WHR is associated with low visceral adipose HMOX1 expression Visceral adipose tissue is more relevant for the development of insulin resistance than subcutaneous adipose tissue. 28 The finding that the gene for cytoprotective and anti-inflammatory enzyme heme oxygenase-1 is less upregulated in visceral compared with subcutaneous adipose tissue lead us to the question whether visceral obesity affects HMOX1 expression within visceral adipose tissue. Owing to high interindividual variation of adipose tissue HMOX1 expression (Figure 2a) , we related visceral adipose tissue expression to that in subcutaneous adipose tissue taking subcutaneous adipose tissue as an individual standard. Relative visceral HMOX1 expression was not significantly different between obese and control subjects in our population but WHR was (obese 0.945 ± 0.034; control 0.893 ± 0.023; P ¼ 0.014). Relative visceral HMOX1 expression in obese subjects negatively correlated with WHR ( Figure 3a ; r ¼ À0. 579, P ¼ 0.024), indicating that the relative amount of visceral fat could affect the relative expression of heme oxygenase-1.
To further investigate the association of WHR and visceral heme oxygenase-1 expression, we divided the whole study population into a WHR low (WHRp0.9, female; WHRp1.0, male; n ¼ 23) and a WHR high (WHR40.9, female; WHR41.0, male; n ¼ 17) group. 29 As shown in Figure 3b , WHR high and low groups highly significantly differed in relative visceral HMOX1 expression. The significant difference in relative visceral HMOX1 expression between subjects with high and low WHR was not only confined to obese (Figure 3c ) but also apparent in controls (Figure 3d ) subjects.
Low visceral HMOX1 expression is associated with insulin resistance
We calculated the relative visceral HMOX1 expression (HMOX1 visc /HMOX1 sc ) as a measure of the ability to Adipose heme oxygenase-1 and insulin sensitivity S Shakeri-Manesch et al upregulate HMOX1 in the metabolically relevant visceral compared with the subcutaneous adipose tissue, which is less prone to obesity-induced alterations, thereby excluding interindividual variations in adipose tissue gene expression in general. To investigate whether relative visceral HMOX1 expression relates to insulin resistance, we analyzed correlations with HOMA-IR. Within obese insulin-resistant subjects (HOMA-IRX3 according to Cotrim et al.
30
) we found a significant correlation between HOMA-IR and relative visceral HMOX1 expression (Figure 4a ; r ¼ 0.643, P ¼ 0.024, n ¼ 16), indicating that insulin resistance is linked to low heme oxygenase-1 expression in visceral obesity.
A significant difference in HOMA-IR was also apparent when the obese group was divided according to the median into high (HMOX1 visc /HMOX1 sc X1.7)-and low (HMOX1 visc / HMOX1 sc o1.7)-relative visceral HMOX1 expression subgroups. As shown in Figure 4b , HOMA-IR significantly differed by about twofold between these subgroups of insulin-resistant obese subjects (P ¼ 0.0017), confirming low visceral HMOX1 expression to be associated with more severe obesity-induced insulin resistance (Figure 4b ). When applying a cutoff level of 2 for the HOMA-IR to select a sufficient number of to some extent insulin-resistant subjects (n ¼ 8) in the control group, there was also a significant difference in HOMA-IR between subjects with high and low visceral HMOX1 expression (Figure 4c ). These data indicate that low visceral adipose heme oxygenase-1 expression relates to insulin resistance independent of body weight. The tight relation of visceral adipose HMOX1expression and HOMA-IR was in trend (P ¼ 0.089), confirmed by a multivariate regression model including WHR.
Discussion
Our data show that obesity is not only associated with the well-known inflammatory response in the adipose tissue, but also with a marked upregulation of the protective enzyme heme oxygenase-1. This upregulation could be a response to hypoxia that occurs in obese adipose tissue, 31,32 because HMOX1 is a target gene of hypoxia-inducible transcription factors. 33 Interestingly, in accordance with adipose tissue macrophages as shown here, also macrophages infiltrating hypoxic areas of human polycystic kidneys markedly express heme oxygenase-1. 34 Importantly, the distribution of body fat, reflected by WHR, affects adipose tissue quality as assessed by HMOX1 expression. Visceral obesity indicated by high WHR is associated with a diminished upregulation of HMOX1 expression levels in visceral adipose tissue, which is primarily prone to be affected by obesity-mediated disturbances such as adipocyte malfunction and death as well as inflammatory responses, 1, 27, 35 as compared with the more stable subcutaneous adipose tissue (Figure 3) . Because of the negative correlation of relative visceral adipose HMOX1 expression with the HOMA-IR (Figure 4 ), heme oxygenase-1 is demonstrated as a presumable factor of visceral adipose tissue quality that is most probably related to its antioxidative activity, albeit our study is limited to gene expression data. Of note, these associations exist not only in morbidly obese, but also in non-obese individuals, indicating that accumulation of visceral fat reduces its ability to dampen oxidative stress and interferes with insulin sensitivity already in the lean individuals. 36 The negative correlation of relative visceral HMOX1 expression and HOMA-IR is evident only in insulin-resistant subjects. The fact that visceral HMOX1 expression did not correlate with HOMA-IR in insulin- Adipose heme oxygenase-1 and insulin sensitivity S Shakeri-Manesch et al sensitive subjects does not necessarily mean that heme oxygenase-1 is not important for insulin sensitivity in such individuals, but suggests that more exact measures of insulin sensitivity, particularly hyperinsulinemic euglycemic clamp testing, should be applied to estimate the putative role of visceral heme oxygenase-1. In conclusion, our data suggest that diminished visceral adipose heme oxygenase-1 expression may be a factor by which visceral obesity leads to insulin resistance. The known cytoprotective, antioxidative and anti-inflammatory properties of the CD163/heme oxygenase-1 system 16, 18 together with the data on its adipose tissue expression presented here, make low heme oxygenase-1 expression a putative powerful marker for detrimental adipose tissue quality. This notion is strongly confirmed by the negative correlation of relative visceral adipose HMOX1 expression with the HOMA-IR (Figure 4) . Moreover, beneficial effects of a heme oxygenase-1 inducer/activator on adiponectin (an anti-inflammatory and insulin-sensitizing adipocyte-specific cytokine 37 ) plasma levels in rats and in vitro adipogenesis have recently been described. 38 Carbon monoxide, a main product of heme oxygenase-1-mediated heme degradation, induces the expression of the transcription factor PPARg in macrophages 39 that drives antiinflammatory activation in macrophages and promotes adipogenesis and adipocyte function. 40, 41 Thus, heme oxygenase-1 has a putative beneficial function in adipose tissue through antioxidative, metabolic and anti-inflammatory mechanisms. Similar to adipose tissue CD163 expression, the serum concentration of the soluble form of CD163 (sCD163) is elevated in obesity (Figure 1d ), as previously shown in patients with chronic kidney disease. 21 However, sCD163
concentrations did not directly correlate with adipose tissue CD163 nor HMOX1 expression (data not shown). As no function has been described so far, sCD163 concentrations can currently be taken as an additional systemic inflammatory marker in obese individuals, but our data fail to give hints of a relationship of sCD163 with the CD163/heme oxygenase-1 system in adipose tissue macrophages. Clearly, further research is warranted to clarify the role of sCD163, particularly in obesity. Macrophage CD163 expression that is known to be regulated by anti-as well as pro-inflammatory stimuli 42 was not apparently altered by obesity (Figure 1c ). This finding is somewhat surprising, as factors inducing CD163 such as interleukin-6 and tumor necrosis factor-a are elevated in the obese adipose tissue, but are in accordance with previous data on CD163 surface expression, which did not correlate with BMI in a small cross-sectional study. 10 One explanation could be that CD163 expression is already very high in adipose tissue macrophages of lean individuals. 10 However, so far very little is known about molecules regulated by obesity in human in contrast to murine adipose tissue macrophages, 13, 43 and thus our results on HMOX1
indicating marked regulation in macrophages upon visceral obesity (Figure 2d ) is of particular interest and warrants further investigation. Such studies may also elucidate whether heme oxygenase-1 is regulate dependent or independent of CD163. Recent animal studies exploring the possibility to use heme oxygenase-1 to treat or prevent obesity-induced insulin resistance show that administration of a heme oxygenase-1 inducers significantly improve insulin sensitivity and other metabolic parameters in mice and rats. 22, 23 Although these improvements were associated with increased plasma adiponectin and decreased inflammatory and oxidative stress markers, these data did not prove an involvement of adipose tissue inflammation and macrophages in the heme oxygenase-1-mediated effects. Moreover, treatment with heme oxygenase-1 inducer caused weight loss in one of these studies that could underlie the metabolic effects. 22 Nonetheless, the results of these studies strongly corroborate the conclusions of our study in humans that visceral adipose tissue heme oxygenase-1 may be a regulator of insulin sensitivity and could be used as a therapeutic target. Together with published findings the following model can be derived from our data: adipose tissue macrophages, which express the hemoglobin scavenger receptor (CD163), upregulate protective heme oxygenase-1 upon obesity. However, accumulation of visceral fat interferes with this protective response by unknown mechanisms, leading to diminished upregulation of visceral heme oxygenase-1 expression that results in a pro-inflammatory environment with increased oxidative stress that predisposes to insulin resistance. More detailed analyses including appropriate animal models and in vitro analyses will reveal the validity of this model and refine our knowledge on underlying mechanisms by which visceral obesity and heme oxygenase-1 repression leads to metabolic deterioration.
